News Network

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss biomarker testing in non–small cell lung cancer.

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss updates in HCC and GI cancers from the 2024 ESMO Congress.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss updates in ALK-positive and ROS1-positive non–small cell lung cancer.

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss updates in acute myeloid leukemia following the 2024 SOHO Annual Meeting.

Yoshiaki Nakamura, MD, PhD, discusses how a methylation-based circulating tumor DNA assay can enhance minimal residual disease detection and improve prognosis in patients with previously treated stage II-III colorectal cancer.

Samuel Cytryn, MD, and David B. Zhen, MD, on updates in gastrointestinal cancers from the 2024 ASCO Annual Meeting and Gastrointestinal Cancers Symposium.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss the real-world use of BTK inhibitors for patients with chronic lymphocytic leukemia.

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the changing treatment landscape of patients with advanced or metastatic HER2-positive breast cancer.

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss updates to the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss advances in treatment options in advanced biliary tract cancer.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for at the upcoming ASCO Annual Meeting in Chicago, with some additional tidbits to round out the main event.

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, explore the advantages of biomarker testing and next-generation sequencing in diagnosing and managing non-small cell lung cancer.

D. Ross Camidge, MD, PhD,of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses research efforts for patients with non–small cell lung cancer who harbor NRG1 fusions.

Christian Marth, MD, PhD, discusses implications of the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

Nikhil I. Khushalani, MD, discusses the diagnosis, outcomes, treatment landscape, and future directions of locally advanced or metastatic cutaneous squamous cell carcinoma.

Experts explore the clinical significance and practical implications of recent findings regarding a CAR T-cell therapy in real-world settings.

Two experts discuss the recent data presented at ASH 2023 on BCMA-targeted CAR-T therapies in relapsed/ refractory multiple myeloma patients.

Cathy Eng, M, FACP, FASCO presents a comprehensive End-of-Year Review in Colorectal Cancer (CRC), delving into the exploration of emerging treatment options and clinical insights on the future landscape. This insightful review includes a focus on the recent approval of fruquintinib and important updates on target therapies for HER2+, BRAF V600E-Mutant, and KRAS-mutant CRC, as well as an interactive Q&A segment.